Krystal (KRYS)
Biotech
Close on Nov 2, 2026 (from our latest article): $295.90
- Market value
- $8.8Bat the Nov 2 close
- Revenue growth
- +26%12 months to Sep 30, 2026 (10-Q)
- FCF margin
- 66%12 months to Sep 30, 2026 (10-Q)
- Net cash
- $1.2Bat Sep 30, 2026
- Worst fall since listing
- −53.4%Mar 1, 2021 to Nov 26, 2021; back to that high in Nov 2021
About the company
Website (external site)Investor relations (external site)SEC filings (external site)
The Long View
Krystal spent its first seven years developing Vyjuvek, funded by share sales, then turned profitable within a year of its 2023 approval.
▲ better · ▼ worse · ⚠ watch, latest quarter · share count · cash
Updated Nov 2, 2026
Our View Opinion
Our analysis of the company and our scenarios for 2030: median value, range, chance of beating the hurdle and the biggest risk.
No Our View yet. Request one →
More of our coverage that names Krystal
Long-term fundamentals
Annual results for Krystal, FY2016–FY2025, as reported in its 10-K filings.
Revenue and free cash flow
Revenue went from $51M in FY2023 to $389M in FY2025.
Free cash flow was positive in 2 of the 10 years shown; FY2025: $189M.
Margins
Operating margin was 41% in FY2025, vs −216% in FY2023.
Diluted share count
The diluted share count rose 59% from FY2020 to FY2025, to 30M.
Results and cash flow
| Fiscal year | Revenue | Gross margin | Operating margin | Net income | Operating cash flow | Capital spending | Free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | $389M | — | 41% | $205M | $201M | $12M | $189M |
| FY2024 | $291M | — | 23% | $89M | $123M | $4M | $119M |
| FY2023 | $51M | — | −216% | $11M | −$89M | $12M | −$101M |
| FY2022 | $0 | — | — | −$140M | −$101M | $53M | −$154M |
| FY2021 | $0 | — | — | −$70M | −$48M | $68M | −$116M |
| FY2020 | — | — | — | −$32M | −$26M | $15M | −$41M |
| FY2019 | — | — | — | −$19M | −$19M | $6M | −$25M |
| FY2018 | — | — | — | −$11M | −$9M | $2M | −$12M |
| FY2017 | — | — | — | −$8M | −$4M | $0.2M | −$4M |
| FY2016 | — | — | — | −$1M | −$1M | $0.0M | −$1M |
Shares, cash, debt and payouts
| Fiscal year | Diluted shares | Cash and investments | Debt | Stock-based pay | Dividends paid | Buybacks |
|---|---|---|---|---|---|---|
| FY2025 | 30M | $956M | — | $55M | — | — |
| FY2024 | 30M | $750M | — | $49M | — | — |
| FY2023 | 28M | $594M | — | $40M | — | — |
| FY2022 | 25M | $384M | — | $33M | — | — |
| FY2021 | 22M | $502M | — | $15M | — | — |
| FY2020 | 19M | $271M | — | $3M | — | — |
| FY2019 | — | $194M | — | $1M | — | — |
| FY2018 | — | $112M | — | $0.8M | — | — |
| FY2017 | — | $50M | — | $0.2M | — | — |
| FY2016 | — | $2M | $2M | $0.0M | — | — |
Source: company 10-K filings via SEC EDGAR (XBRL data); fiscal years. Data fetched Nov 2, 2026. Free cash flow is operating cash flow minus capital spending (our calculation; the company's own definition may differ). Margins are a share of revenue. "—" means the figure is not in the 10-K data.
Returns by year
| Year | KRYS | S&P 500 |
|---|---|---|
| 2019 | +166.5% | +31.5% |
| 2020 | +8.3% | +18.4% |
| 2021 | +16.6% | +28.7% |
| 2022 | +13.3% | −18.1% |
| 2023 | +56.6% | +26.3% |
| 2024 | +26.3% | +25.0% |
| 2025 | +57.4% | +17.9% |
| 2026 to date | +28.1% | +5.9% |
Total return, with dividends reinvested: each year from the last close of the year before to the last close of the year; 2026 to date runs to the Nov 19, 2026 close. The S&P 500 is its total return index. Our calculation from Yahoo Finance daily closes and adjusted closes; not investment advice.
Other companies we cover in Biotech
- CORT Corcept Therapeutics Down 20.1%
- TGTX TG Therapeutics Up 5.9%
- MDGL Madrigal Down 8.1%
- ARWR Arrowhead Down 15.3%
- IOVA Iovance Down 35.4%
- TNGX Tango Therapeutics Down 16.4%
Show all 17
- SLS SELLAS Up 156.4%
- ALNY Alnylam
- VKTX Viking Therapeutics
- GMAB Genmab Up 28.3%
- XNCR Xencor Up 15.9%
- VERA Vera Down 1.2%
- NRIX Nurix Therapeutics Down 38.2%
- AGIO Agios Down 9.9%
- IMCR Immunocore Up 9.1%
- ORIC ORIC Pharmaceuticals Down 32%
- MRNA Moderna Down 17.6%
Questions about Krystal
- How does Krystal Biotech make money?
- Almost entirely from one product, Vyjuvek, a gene therapy gel applied to the wounds of people with dystrophic epidermolysis bullosa (DEB), a rare genetic skin disease. Vyjuvek brought in $470 million of revenue in the 12 months to September 2026; Krystal has no other approved product. More in the Long View →
- Where is Krystal's growth coming from?
- Outside the US. In the first nine months of 2026, US Vyjuvek sales were about 1% lower than a year earlier, while sales in Europe and Japan, where Vyjuvek launched in late 2025, made up about a quarter of revenue. Krystal is also testing the same gene-delivery technology in eye, lung, skin and cancer programs. More in the Long View →
- What could slow Krystal's growth?
- Its dependence on a single product sold mostly through one US specialty pharmacy, competing DEB treatments approved in 2023 and 2025, pricing negotiations in Europe, and pipeline trials that have repeatedly taken longer than planned. A US Department of Justice inquiry into a Vyjuvek genetic-testing program is unresolved. More in the Long View →
- What is Jeune Aesthetics?
- A wholly owned Krystal subsidiary that is testing injections of the same type of gene-delivery vector for cosmetic uses, such as wrinkles on the upper chest. Krystal said in September 2026 that it had paused Jeune to focus on its rare-disease trials and was seeking a partner. Its products are investigational: none is approved, the data come from small company-run early trials, and long-term safety in healthy people is not yet established. More in the Long View →
- Has Krystal diluted its shareholders?
- Yes, heavily before Vyjuvek was approved: shares outstanding rose about 48% from the end of 2020 to the end of 2025, mainly from share sales in 2021–2023 to fund development. It has sold no shares for cash since 2023 and in November 2026 authorized up to $400 million of buybacks. More in the Long View →
- What's coming up for Krystal Biotech's pipeline in the next 12 months?
- Krystal expects interim KB111 results in Hailey-Hailey disease before the end of 2026; the last patient visit in its registrational KB803 eye study in February 2027, with top-line results shortly after; interim KB407 cystic fibrosis results in the first half of 2027; and to start registrational studies of KB407 and KB111 in 2027. It expects KB801 top-line results in 2027. As of Nov 2, 2026 More in the Long View →